Inscripta, Inc.

Inscripta, Inc. , headquartered in Pleasanton, US, innovates in gene editing technology, offering solutions that integrate Directed Evolution, CRISPR+, and Machine Learning for biomanufacturing applications. Inscripta, Inc. is dedicated to advancing gene editing technologies.

Founded in 2015 by Andrew Garst, the company has pursued a trajectory of innovation in the biotechnology sector. It has undertaken 10 notable deals, with the most recent funding round completed in December 2022, raising USD 27. 79 mn. Sri Kosaraju currently serves as CEO, steering the company through its growth phase.

Inscripta® specializes in advanced biomanufacturing technologies, leveraging a unique approach known as Lean Bioengineering™, which combines Directed Evolution, CRISPR+, and Machine Learning. Their flagship product, GenoScaler™, is designed to identify and recombine genetic edits, creating strains with the highest commercial potential for various applications. This technology enables rapid testing of large sets of genetic solutions, significantly improving traits in biomanufactured products. Inscripta® serves a diverse client base that includes biotechnology firms, pharmaceutical companies, and agricultural enterprises looking to innovate and enhance their product offerings.

The company distributes its products primarily in North America and Europe, addressing the growing demand for sustainable biomanufacturing solutions in global markets. Inscripta® generates revenue through direct business transactions with clients primarily in the biotechnology and agricultural sectors. The company's revenue structure is based on partnerships and collaborations, where clients engage with Inscripta® for access to their proprietary technologies, including GenoScaler™. These transactions typically involve service agreements and project-based pricing for the development and optimization of customized genetic solutions.

Inscripta®'s business model focuses on delivering value through innovative solutions that enhance biomanufacturing processes, promoting efficiency and cost-effectiveness for its clients. Specific pricing details and transaction values are not disclosed, reflecting the company’s strategic approach to maintaining competitive advantage in the market. Inscripta, Inc. plans to leverage the USD 27.

79 mn raised in December 2022 to expand its product offerings and enhance its market reach. The company is actively designing new products aimed at optimizing biomanufacturing processes, although specific launch dates have not been disclosed. Additionally, Inscripta® is targeting expansion into key markets in Asia and South America by the end of 2024, aiming to establish a broader presence in these emerging regions.